URO-1, Inc. is a privately held medical device company founded with the mission to innovate and improve office-based urology and urogynecology procedures. The company's vision is to provide breakthrough solutions that enhance diagnostic accuracy and treatment efficacy. URO-1's initial product offerings include advanced devices for prostate biopsy in men and treatments for overactive bladder (OAB) in women. These products aim to address common issues such as inadequate biopsy samples and inefficient diagnostic processes, ultimately reducing costs and improving patient outcomes.

Notable figures associated with URO-1 include leading experts in urology and medical device innovation, though specific names are not publicly disclosed. The company has attracted significant interest from investors focused on healthcare technology. Key achievements include the development of devices that offer higher tissue quality, minimize fragmentation, and preserve tissue integrity, which have been well-received in clinical settings. URO-1's impact lies in its potential to streamline urological diagnostics and treatments, thereby enhancing the efficiency of healthcare systems and improving patient care.